- Home
- NMRA vs ANNX Comparison
NMRA vs ANNX Comparison
Compare NMRA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- ANNX
- Stock Information
- Founded
- NMRA 2019
- ANNX 2011
- Country
- NMRA United States
- ANNX United States
- Employees
- NMRA N/A
- ANNX N/A
- Industry
- NMRA
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- ANNX Health Care
- Exchange
- NMRA Nasdaq
- ANNX Nasdaq
- Market Cap
- NMRA 234.5M
- ANNX 263.3M
- IPO Year
- NMRA 2023
- ANNX 2020
- Fundamental
- Price
- NMRA $2.08
- ANNX $2.59
- Analyst Decision
- NMRA Buy
- ANNX Strong Buy
- Analyst Count
- NMRA 8
- ANNX 4
- Target Price
- NMRA $7.14
- ANNX $12.50
- AVG Volume (30 Days)
- NMRA 2.2M
- ANNX 1.9M
- Earning Date
- NMRA 08-06-2025
- ANNX 08-11-2025
- Dividend Yield
- NMRA N/A
- ANNX N/A
- EPS Growth
- NMRA N/A
- ANNX N/A
- EPS
- NMRA N/A
- ANNX N/A
- Revenue
- NMRA N/A
- ANNX N/A
- Revenue This Year
- NMRA N/A
- ANNX N/A
- Revenue Next Year
- NMRA N/A
- ANNX N/A
- P/E Ratio
- NMRA N/A
- ANNX N/A
- Revenue Growth
- NMRA N/A
- ANNX N/A
- 52 Week Low
- NMRA $0.61
- ANNX $1.29
- 52 Week High
- NMRA $17.19
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- NMRA 70.06
- ANNX 54.54
- Support Level
- NMRA $1.70
- ANNX $2.37
- Resistance Level
- NMRA $2.85
- ANNX $2.61
- Average True Range (ATR)
- NMRA 0.32
- ANNX 0.19
- MACD
- NMRA 0.05
- ANNX -0.01
- Stochastic Oscillator
- NMRA 58.08
- ANNX 71.70
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.